Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Smart pill bottles and video visits boost cancer drug adherence

NCT ID NCT04054557

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether using telehealth visits and smart pill bottles can help breast cancer patients take their hormone therapy as prescribed. 305 women and men with early-stage hormone receptor-positive breast cancer participated. They either had regular in-person checkups or virtual visits with their oncologist and used electronic pill bottles to track medication. The goal was to see if this approach improves adherence and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
telehealth (video visits with oncologist) and smart pill bottles
What this could lead to
If it works, this approach could help breast cancer patients take their hormone therapy more consistently, potentially improving treatment outcomes and quality of life.
What could go wrong
This is a completed phase II trial, so results are available but not yet widely implemented. The benefit may vary by patient, and telehealth may not suit everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

305 people

The number who actually took part.

Started

Jul 2019

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * • Signed informed consent obtained prior to any study specific assessments and procedures * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Women or men diagnosed with stage 0-III hormone receptor positive (estrogen receptor positive \[ER\] and /or progesterone receptor \[PR\] positive) breast cancer \* Staging for eligibility should utilize the most recent American Joint Committee on Cancer (AJCC) breast cancer staging version * Patients (Pts) must have undergone breast surgery for their diagnosis of breast cancer * Adjuvant endocrine therapy has been prescribed by their treating physician \* Patients may receive concurrent adjuvant radiation therapy plus endocrine therapy in the post-operative setting * Have a cell phone with text messaging ability * Have access to a computer, tablet, or smart phone to complete electronic surveys * Patient must be willing to setup an online Jefferson MyChart account * Patients who have been on endocrine therapy for more than 4 years Exclusion Criteria: * Pts with stage IV metastatic breast cancer * Patients unable to participate in patient portal communication (e.g. do not have either a smart phone, laptop, access to a computer and/ or access to a device with a webcam) * Pts who are non-English speaking and English illiterate

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Stage 0 breast cancer ajcc V6 and V7 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Jefferson Health - Asplundh Cancer Pavilion

    Willow Grove, Pennsylvania, 19090, United States

  • Jefferson Health - Northeast

    Torresdale, Pennsylvania, 19114, United States

  • Jefferson Health - South Jersey

    Washington Township, New Jersey, 08080, United States

  • Methodist Hospital

    Philadelphia, Pennsylvania, 19148, United States

  • Thomas Jefefrson University

    Philadelphia, Pennsylvania, 19107, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.